Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
- Registration Number
- NCT02811510
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
- Detailed Description
To characterize the acute effects of oral Dronabinol (10 mg capsule) in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
- At least one lifetime exposure to cannabis
- Good physical and mental health
- Cannabis naive individuals
- Major current or recent stressors
- Taking estrogen supplements or oral contraceptive pills (for women)
- Sesame oil allergy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo pill (no active cannabinoids). THC Dronabinol 10 mg Dronabinol will be administered orally.
- Primary Outcome Measures
Name Time Method Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT) baseline and +80 minutes after start of oral Dronabinol administration. Measured as delay recall on the AVLT
Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS) changes in "high" assessed over the following timepoints: baseline, +60, +80, +120, +180, +300 minutes after start of oral Dronabinol administration. Subjective measure of THC induced "high"
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
🇺🇸West Haven, Connecticut, United States